New Bioinformatics Platform‐Based Approach for Drug Design
Vivek P. Chavda, Soham Sheta, Divyesh Changani, Disha Chavda · 2021
There is ample growth potential in the current biologics era. There are more than 1,600 biologics under evaluation where over 250 approved drugs and many more drugs are in the pipeline. Many genomes have been mapped with the aid of bio-informatics tools. Such advancements have triggered the research at the level of transcriptome and protein engineering. The journey of finding new viable protein drug starts from the virtual screening of the targets/lead, optimizing them, and making them commercially viable. An approach called rational drug design is now integrated with computer-aided drug design under the umbrella of molecular docking. Computer-aided drug design which is also known as in silico method is further being bifurcated in to ligand-based and structure-based screening. Nowadays, ligand-based (pharmacophore) and structure-based (molecular docking) screening have merged into a platform that involves the processes of finding new target discovery for achieving promising leads. This chapter encompasses current approaches for drug design and their interrelationship for drug discovery process.